OBJECTIVE: Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. METHODS: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. RESULTS: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. CONCLUSIONS: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.
OBJECTIVE:Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. METHODS: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. RESULTS: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. CONCLUSIONS: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.
Authors: Michael A Schwarzschild; Kui Xu; Emin Oztas; Jacobus P Petzer; Kay Castagnoli; Neal Castagnoli; Jiang-Fan Chen Journal: Neurology Date: 2003-12-09 Impact factor: 9.910
Authors: Jordan J Elm; Christopher G Goetz; Bernard Ravina; Kathleen Shannon; George Fredrick Wooten; Caroline M Tanner; Yuko Y Palesch; Peng Huang; Paulo Guimaraes; Cornelia Kamp; Barbara C Tilley; Karl Kieburtz Journal: Ann Neurol Date: 2005-02 Impact factor: 10.422
Authors: G W Ross; R D Abbott; H Petrovitch; D M Morens; A Grandinetti; K H Tung; C M Tanner; K H Masaki; P L Blanchette; J D Curb; J S Popper; L R White Journal: JAMA Date: 2000 May 24-31 Impact factor: 56.272
Authors: A H Evans; A D Lawrence; J Potts; L MacGregor; R Katzenschlager; K Shaw; J Zijlmans; A J Lees Journal: J Neurol Neurosurg Psychiatry Date: 2006-03 Impact factor: 10.154
Authors: Kang-Woo Lee; Joo-Young Im; Jong-Min Woo; Hilary Grosso; Yoon-Seong Kim; Ana Clara Cristovao; Patricia K Sonsalla; David S Schuster; Marla M Jalbut; Jose R Fernandez; Michael Voronkov; Eunsung Junn; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian Journal: Neurotherapeutics Date: 2013-01 Impact factor: 7.620
Authors: David K Simon; Cai Wu; Barbara C Tilley; Katja Lohmann; Christine Klein; Haydeh Payami; Anne-Marie Wills; Michael J Aminoff; Jacquelyn Bainbridge; Richard Dewey; Robert A Hauser; Susen Schaake; Jay S Schneider; Saloni Sharma; Carlos Singer; Caroline M Tanner; Daniel Truong; Peng Wei; Pei Shieen Wong; Tianzhong Yang Journal: J Neurol Sci Date: 2017-02-17 Impact factor: 3.181
Authors: Anne-Marie A Wills; Shirley Eberly; Marsha Tennis; Anthony E Lang; Susan Messing; Daniel Togasaki; Caroline M Tanner; Cornelia Kamp; Jiang-Fan Chen; David Oakes; Michael P McDermott; Michael A Schwarzschild Journal: Mov Disord Date: 2013-01-21 Impact factor: 10.338
Authors: Christopher C Wendler; Melissa Busovsky-McNeal; Satish Ghatpande; April Kalinowski; Kerry S Russell; Scott A Rivkees Journal: FASEB J Date: 2008-12-16 Impact factor: 5.191
Authors: David K Simon; Cai Wu; Barbara C Tilley; Anne-Marie Wills; Michael J Aminoff; Jacquelyn Bainbridge; Robert A Hauser; Jay S Schneider; Saloni Sharma; Carlos Singer; Caroline M Tanner; Daniel Truong; Pei Shieen Wong Journal: Clin Neuropharmacol Date: 2015 Sep-Oct Impact factor: 1.592
Authors: Natalia Palacios; Xiang Gao; Marjorie L McCullough; Michael A Schwarzschild; Roma Shah; Susan Gapstur; Alberto Ascherio Journal: Mov Disord Date: 2012-08-27 Impact factor: 10.338